The Spineway Group, a specialist in revolutionary implants for the remedy of extreme spine problems, declares the accelerated rollout of its vary of VEOS implants for intervertebral fixation by posterior strategy into new markets.
This know-how, which addresses the most important section of the spine implant market, estimated to be value almost US$12 billion,1 has obtained CE/MD marking and 510(ok) clearance from the US Food and Drug Administration (FDA). On the power of those approvals, Spineway is rolling out gross sales of its VEOS system in France, by way of direct gross sales to healthcare services, in addition to in Europe and the export market by way of a community of importer-distributors.
First implants in Spain
In Spain, the distribution of the VEOS vary has been entrusted to one of many main gamers within the distribution of orthopedic and spinal implants, and the primary implants had been carried out on sufferers in hospitals in Barcelona on November 13 and 15. These operations went effectively, and the Spanish surgeons had been very glad with the VEOS devices and implants, which enabled them to carry out the correction and fixation procedures that they had deliberate for his or her sufferers with precision. These first profitable surgical procedures affirm the nice match between Spineway merchandise and the wants of the Spanish spine surgical procedure market.
New approvals in Colombia and Indonesia
Supported by US FDA approval in October 20232 and the product displays given on the NASS (North American Backbone Society) Congress in Los Angeles,3 the Spineway Group has simply obtained approvals from well being authorities for the VEOS vary to be marketed in Colombia and Indonesia. Entry into these new markets ought to contribute to gross sales progress for this vary in 2024 and strengthen the Group’s positions in Latin America and Asia.
These new achievements consolidate Spineway’s place within the discipline of spine surgical procedure and ensure its purpose of turning into an revolutionary participant in France and internationally, a pacesetter in much less invasive spine therapies.
SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES) Discover out all about Spineway at www.spineway.com
This press launch has been ready in each English and French. In case of discrepancies, the French model shall prevail.
Spineway designs, manufactures and markets revolutionary implants and surgical devices for treating extreme problems of the spinal column. Spineway has a global community of over 50 unbiased distributors and 90% of its income comes from exports. Spineway, which is eligible for funding by way of FCPIs (French unit trusts specializing in innovation), has obtained the OSEO Excellence award since 2011 and has gained the Deloitte Quick 50 award (2011). Rhône Alpes INPI Patent Innovation award (2013) – INPI Expertise award (2015). ISIN: FR001400BVK2 – ALSPW
Accessible Tuesday by way of Thursday
+33 (0)806 706 060
1 Supply: iData Market Analysis 2022 2 Press launch of October 19, 2023 3 Press launch of November 2, 2023